Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab.
BMJ Case Rep
; 14(9)2021 Sep 03.
Article
in English
| MEDLINE | ID: covidwho-1394072
ABSTRACT
Ado-trastuzumab emtansine (T-DM1) is a monoclonal antibody drug conjugate approved for the treatment of HER2-positive breast cancers. Presented here is a case report of a patient who developed fatal pulmonary toxicity in the form of acute eosinophilic pneumonia while undergoing treatment with T-DM1. Prior to beginning T-DM1 therapy, this patient had been treated with two HER2-targeted agents (trastuzumab, pertuzumab) per National Comprehensive Cancer Network (NCCN) guidelines. This case represents a novel presentation of toxicity associated with T-DM1 while perhaps demonstrating additive toxicity associated with multiple lines of HER2 targeted therapies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Eosinophilia
/
Breast Neoplasms
/
Maytansine
Type of study:
Case report
/
Diagnostic study
Limits:
Female
/
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-243881
Similar
MEDLINE
...
LILACS
LIS